Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;71(3):270-275.
doi: 10.5173/ceju.2018.1749. Epub 2018 Sep 22.

Low-dose-rate brachytherapy as a minimally invasive curative treatment for localised prostate cancer has excellent oncological and functional outcomes: a retrospective analysis from a single centre

Pieter D'hulst  1 , Pieter Mattelaer  1 , Jochen Darras  1 , Lorenzo Staelens  2 , Hans Pottel  3 , Diederik Ponette  1
Affiliations

Low-dose-rate brachytherapy as a minimally invasive curative treatment for localised prostate cancer has excellent oncological and functional outcomes: a retrospective analysis from a single centre

Pieter D'hulst et al. Cent European J Urol. 2018.

Abstract

Introduction: Low-dose-rate (LDR) brachytherapy is a widely used therapeutic option for localised prostate cancer. The aim of this study was to analyse the oncological and functional outcomes after 10 years of experience with brachytherapy for localised prostate cancer.

Material and methods: All patients who underwent brachytherapy between April 2006 and September 2017 were included for analysis. Initial prostate-specific antigen (PSA) levels, tumour stages, Gleason scores, positive biopsies, prostate volumes, dosimetric parameters, and urinary symptoms were noted.

Results: A total of 201 patients underwent brachytherapy between April 2006 and September 2017. Of these patients, 159 had >3 years of oncological and functional follow-up. Only these relevant patients were included in the statistical analysis. This showed a significant, persistent decline in PSA levels (p <0.0001): the mean PSA was 1.2 ng/ml after 6 months, 1.1 ng/ml after 1 year, and 0.49 ng/ml after 3 years. Only 9 patients had tumour recurrence (3 patients with Gleason score 6 and 6 patients with Gleason score 7). After receiving adequate treatment, the patients underwent oncological follow-up.Important obstructive and irritative complaints were most pronounced during the first 9 months and decreased strongly after 18 months of follow-up.

Conclusions: LDR brachytherapy has excellent oncological outcomes with limited functional inconveniences that are adequately treatable. Our 10 years' experience shows that brachytherapy is a safe and effective method for the treatment of low-risk localised prostate cancer.

Keywords: brachytherapy; functional outcomes; oncological outcomes; prostate cancer; prostate-specific antigen.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution of mean prostate-specific antigen (PSA) levels.
Figure 2
Figure 2
Kaplan-Meier curve of recurrence-free survival. CI – confidence interval; NE – not estimable; KM – Kaplan-Meier; patient-at risk: all patients (159) who were icluded for statistical analysis
See this image and copyright information in PMC

References

    1. Wong MC, Goggins WB, Wang HH, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862–874. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386. - PubMed
    1. National Comprehensive Cancer Network . Prostate Cancer, Practice Guidelines in Oncology. 2016. v. 3.2016.
    1. Whitmore WF, Jr, Hilaris B, Grabstald H. Retropubic implantation of iodine 125 in the treatment of prostate cancer. J Urol. 1972;108:918–920. - PubMed
    1. Holm HH, Juul N, Pederson JF, Hansen H, Stroyer I. Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol. 1983;130:283–2861. - PubMed

LinkOut - more resources